JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1993; 21:255-259
© 1993 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnstone, M.
Right arrow Articles by Waters, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnstone, M.
Right arrow Articles by Waters, D

Methylene blue inhibits the antithrombotic effect of nitroglycerin

MT Johnstone, JY Lam, L Lacoste, J Baribeau, P Theroux, and D Waters

Department of Medicine, University of Montreal, Quebec, Canada.

OBJECTIVES. The aim of this study was to examine whether cyclic guanosine monophosphate (GMP) may be involved in the antithrombotic action of nitroglycerin. BACKGROUND. Nitroglycerin has been shown to inhibit platelet function in vitro by stimulating prostacyclin or inhibiting thromboxane A2 production, or both. Nitroglycerin has also been shown to possess potent antithrombotic properties in vivo. However, the mechanism of this antithrombotic effect is unclear. METHODS. Nitroglycerin was infused to produce a 10% decrease in mean arterial pressure in 27 normal pigs by exposing their circulating arterial blood to porcine aortic media in an ex vivo perfusion chamber. Eight pigs received an infusion of nitroglycerin alone; eight received an infusion of methylene blue, a guanylate cyclase inhibitor, followed by nitroglycerin infusion and five pigs received an infusion of nitroglycerin followed by methylene blue and subsequent infusion of cyclic GMP. RESULTS. With nitroglycerin alone, quantitative autologous indium-111-labeled platelet deposition (x10(6) on the aortic media was decreased to 63.9 +/- 10.4% (p = 0.01) of the baseline control platelet deposition. Methylene blue given before nitroglycerin tended to increase platelet deposition relative to baseline and platelet deposition after nitroglycerin was 142 +/- 35% (p = NS) of baseline value. In pigs that received all three agents, nitroglycerin reduced platelet deposition to 42.3 +/- 12.2% of baseline value; this decrease was then attenuated by subsequent methylene blue infusion but was enhanced by cyclic GMP infusion to 16.4 +/- 3.8% of baseline value (p = 0.006 vs. baseline control and p = 0.02 versus methylene blue infusion). CONCLUSIONS. Guanylate cyclase inhibition with methylene blue abolishes the antithrombotic effect of nitroglycerin, which can be enhanced by cyclic GMP.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
D. Hebert and J. Y. T. Lam
Nitroglycerin rebound associated with vascular, rather than platelet, hypersensitivity
J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2311 - 2316.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Hebert, J.-X. Xiang, and J. Y.T. Lam
Persistent Inhibition of Platelets During Continuous Nitroglycerin Therapy Despite Hemodynamic Tolerance
Circulation, March 4, 1997; 95(5): 1308 - 1313.
[Abstract] [Full Text]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. A. Barber, J. W. Rubin, G. L. Zumbro, and R. L. Tackett
The use of methylene blue as an extravascular surgical marker impairs vascular responses of human saphenous veins
J. Thorac. Cardiovasc. Surg., January 1, 1995; 109(1): 21 - 29.
[Abstract] [Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1993 by the American College of Cardiology Foundation.